RISPERIDONE TEVA L.P. 25 mg/2 ml, powder and solvent for injectable suspension with extended release in a pre-filled syringe bottle, 2 ml
Active ingredients: Risperidone
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Powder and solvent for injectable suspension with extended releasebottle, 2 mlintramusculaire
Out of stock
Package details
Original BDPM fields are shown in French.
- Official name
- RISPERIDONE TEVA L.P. 25 mg/2 ml, poudre et solvant pour suspension injectable à libération prolongée en seringue préremplie
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon(s) en verre avec adaptateur(s) pour flacon avec aiguille(s) - 1 seringue(s) préremplie(s) en verre de 2 ml
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 4 Aug 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61515919CIP73021800CIP133400930218006Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RISPÉRIDONEpoudre | 25 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.